sulpiride has been researched along with Weight Gain in 31 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms." | 9.12 | Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006) |
| "To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial." | 9.12 | A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "Sixty outpatients with chronic schizophrenia who had been treated with either amisulpride or olanzapine for at least six months were investigated." | 7.74 | Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007) |
| "To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals." | 7.70 | Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride. ( Baptista, T; Hernández, L; LaCruz, A, 1998) |
| "5-16 mg/kg/ip for 21 days) (a) affects body weight and food intake in gonadally-intact and drug-free female rats, (b) prevents obesity, hyperphagia, hyperprolactinemia and vaginal cycle disruption induced by long-term administration of the antipsychotic drug sulpiride (SUL, 20 mg/kg/ip for 21 days), or (c) reverses the acute hyperphagia induced by SUL (15 microg bilaterally), when directly applied in the perifornical lateral hypothalamus (PFLH)." | 7.70 | Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. ( Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM, 2000) |
| "Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation." | 6.75 | Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010) |
| "Excessive body weight gain, hyperprolactinemia and low gonadal steroid serum levels are often observed during chronic administration of antipsychotic drugs (AP)." | 6.69 | Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. ( Angeles, F; Baptista, T; de Mendoza, S; Hernández, L; Lacruz, A; Mendoza Guillén, JM; Mendoza, MT; Silvera, R, 2000) |
| "We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms." | 5.12 | Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006) |
| "To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial." | 5.12 | A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006) |
| " The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria." | 5.09 | A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. ( Cavagnini, F; Clemente, A; Ferrari, VM; Laini, V; Lugo, F; Mantero, M; Mauri, MC; Redaelli, G; Ruggiero, GM; Zappulli, D, 2001) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| " Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found." | 4.86 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. ( Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| " First, in preclinical experiments in female rats the estradiol antagonist/agonist drug tamoxifen or estradiol itself have been shown to completely prevent the obesity provoked by the AP sulpiride, and to induce an endocrine-metabolic milieu that seems to counteract AP-induced obesity." | 4.80 | Body weight gain induced by antipsychotic drugs: mechanisms and management. ( Baptista, T, 1999) |
| " Clozapine seems to have the highest risk of weight gain, followed by olanzapine and quetiapine." | 4.80 | Atypical antipsychotics and weight gain--a systematic review. ( McAskill, R; Taylor, DM, 2000) |
| "Sixty outpatients with chronic schizophrenia who had been treated with either amisulpride or olanzapine for at least six months were investigated." | 3.74 | Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007) |
| "To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals." | 3.70 | Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride. ( Baptista, T; Hernández, L; LaCruz, A, 1998) |
| "During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain." | 3.70 | Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999) |
| "5-16 mg/kg/ip for 21 days) (a) affects body weight and food intake in gonadally-intact and drug-free female rats, (b) prevents obesity, hyperphagia, hyperprolactinemia and vaginal cycle disruption induced by long-term administration of the antipsychotic drug sulpiride (SUL, 20 mg/kg/ip for 21 days), or (c) reverses the acute hyperphagia induced by SUL (15 microg bilaterally), when directly applied in the perifornical lateral hypothalamus (PFLH)." | 3.70 | Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. ( Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM, 2000) |
| "The weight gain and hyperphagia induced by chronic administration of sulpiride in female rats were not prevented by the concomitant administration of an extra source of sodium." | 3.69 | Hyponatremia and neuroleptic-induced obesity in rats. ( Baptista, T; Catalán, M; Hernández, L; Silva, E; Teneud, L, 1994) |
| "Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation." | 2.75 | Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010) |
| "Excessive body weight gain, hyperprolactinemia and low gonadal steroid serum levels are often observed during chronic administration of antipsychotic drugs (AP)." | 2.69 | Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. ( Angeles, F; Baptista, T; de Mendoza, S; Hernández, L; Lacruz, A; Mendoza Guillén, JM; Mendoza, MT; Silvera, R, 2000) |
| "Sulpiride treatment inhibited the incidence of uterine adenocarcinoma and precancerous lesions of atypical endometrial hyperplasia, whereas EGME had no effect on uterine carcinogenesis." | 1.43 | Effects of sulpiride and ethylene glycol monomethyl ether on endometrial carcinogenicity in Donryu rats. ( Inoue, K; Sakamoto, Y; Takahashi, M; Taketa, Y; Taya, K; Watanabe, G; Yoshida, M, 2016) |
| "Weight gain was predicted by low mean (SD) baseline reward-related activity in the right-sided putamen (0." | 1.43 | Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. ( Ebdrup, BH; Glenthøj, B; Nielsen, MØ; Rostrup, E; Wulff, S, 2016) |
| "1." | 1.30 | Mechanism of the neuroleptic-induced obesity in female rats. ( Acosta, A; Albornoz, MA; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; LaCruz, A; Páez, X; Teneud, L, 1998) |
| " The present experiments extend these findings by investigating: (a) interactions between isolation rearing and repeated handling/testing on presynaptic DA function in the NAC using in vivo microdialysis: (b) the dose-response curve for the effects of d-amphetamine, and the responses elicited by high potassium, using in vivo microdialysis, and (c) postsynaptic function in isolates as indexed by DA receptor-linked cAMP production." | 1.30 | Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. ( Hall, FS; Humby, T; Inglis, W; Kendall, DA; Marsden, CA; Robbins, TW; Wilkinson, LS, 1998) |
| "Pretreatment with sulpiride (32 mg/kg, p." | 1.29 | A screening concept based on a hypothesis led to the development of a putative cognitive enhancer that stimulates penile erection. ( Arakawa, H; Maeda, N; Matsuoka, N; Ohkubo, Y; Yamaguchi, I; Yamazaki, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (25.81) | 18.2507 |
| 2000's | 14 (45.16) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, H | 1 |
| Zapata, RC | 1 |
| Lopez-Valencia, M | 1 |
| Aslanoglou, D | 1 |
| Farino, ZJ | 1 |
| Benner, V | 1 |
| Osborn, O | 1 |
| Freyberg, Z | 1 |
| McCarthy, MJ | 1 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 1 |
| Taketa, Y | 1 |
| Inoue, K | 1 |
| Takahashi, M | 1 |
| Sakamoto, Y | 1 |
| Watanabe, G | 1 |
| Taya, K | 1 |
| Yoshida, M | 1 |
| Kapur, S | 1 |
| Marques, TR | 1 |
| Nielsen, MØ | 1 |
| Rostrup, E | 1 |
| Wulff, S | 1 |
| Glenthøj, B | 1 |
| Ebdrup, BH | 1 |
| Bhowmick, S | 1 |
| Hazra, A | 1 |
| Ghosh, M | 1 |
| Rummel-Kluge, C | 1 |
| Komossa, K | 1 |
| Schwarz, S | 1 |
| Hunger, H | 1 |
| Schmid, F | 1 |
| Lobos, CA | 1 |
| Kissling, W | 2 |
| Davis, JM | 1 |
| Leucht, S | 2 |
| Ružić, K | 1 |
| Dadić-Hero, E | 1 |
| Grahovac, T | 1 |
| Sabljić, V | 1 |
| Kosec, T | 1 |
| Knez, R | 1 |
| Lee, SJ | 1 |
| Lee, JH | 1 |
| Jung, SW | 1 |
| Koo, BH | 1 |
| Choi, TY | 1 |
| Lee, KH | 1 |
| Ng, KF | 1 |
| Innis, SM | 1 |
| Wagenpfeil, S | 1 |
| Hamann, J | 1 |
| Mortimer, AM | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Olié, JP | 1 |
| Spina, E | 1 |
| Murray, S | 1 |
| Yang, R | 1 |
| Papadimitriou, GN | 1 |
| Theleritis, CG | 1 |
| Dikeos, DG | 1 |
| Psarros, CJ | 1 |
| Soldatos, CR | 1 |
| Vanelle, JM | 1 |
| Douki, S | 1 |
| Hofer, A | 1 |
| Rettenbacher, MA | 1 |
| Edlinger, M | 1 |
| Huber, R | 1 |
| Bodner, T | 1 |
| Kemmler, G | 1 |
| Sachs, G | 1 |
| Fleischhacker, WW | 1 |
| Linden, M | 1 |
| Eich, FX | 1 |
| Pyrkosch, L | 1 |
| Silva, E | 1 |
| Catalán, M | 1 |
| Hernández, L | 6 |
| Teneud, L | 2 |
| Baptista, T | 7 |
| Maeda, N | 1 |
| Matsuoka, N | 1 |
| Yamazaki, M | 1 |
| Arakawa, H | 1 |
| Ohkubo, Y | 1 |
| Yamaguchi, I | 1 |
| Contreras, Q | 1 |
| Albornoz, MA | 1 |
| Acosta, A | 2 |
| Páez, X | 1 |
| de Quijada, M | 2 |
| LaCruz, A | 4 |
| Hall, FS | 1 |
| Wilkinson, LS | 1 |
| Humby, T | 1 |
| Inglis, W | 1 |
| Kendall, DA | 1 |
| Marsden, CA | 1 |
| Robbins, TW | 1 |
| Wetterling, T | 1 |
| Müssigbrodt, HE | 1 |
| Colasante, C | 1 |
| de Mendoza, S | 2 |
| Mendoza, JM | 1 |
| Mendoza Guillén, JM | 1 |
| Silvera, R | 1 |
| Angeles, F | 1 |
| Mendoza, MT | 1 |
| Taylor, DM | 1 |
| McAskill, R | 1 |
| Ruggiero, GM | 1 |
| Laini, V | 1 |
| Mauri, MC | 1 |
| Ferrari, VM | 1 |
| Clemente, A | 1 |
| Lugo, F | 1 |
| Mantero, M | 1 |
| Redaelli, G | 1 |
| Zappulli, D | 1 |
| Cavagnini, F | 1 |
| Parada, MA | 1 |
| Puig de Parada, M | 1 |
| Murzi, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for sulpiride and Weight Gain
| Article | Year |
|---|---|
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinic | 2010 |
How do we choose between atypical antipsychotics? The advantages of amisulpride.
Topics: Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
Body weight gain induced by antipsychotic drugs: mechanisms and management.
Topics: Animals; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Endocrine System; Estr | 1999 |
Atypical antipsychotics and weight gain--a systematic review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
7 trials available for sulpiride and Weight Gain
| Article | Year |
|---|---|
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Drug Admi | 2010 |
A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Topics: Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Disea | 2012 |
Amisulpride is an "atypical" antipsychotic associated with low weight gain.
Topics: Amisulpride; Antipsychotic Agents; Databases as Topic; Dose-Response Relationship, Drug; Humans; Mal | 2004 |
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Sympto | 2006 |
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depres | 2006 |
Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.
Topics: Adult; Antipsychotic Agents; Estradiol; Female; Follicle Stimulating Hormone; Hormones; Humans; Insu | 2000 |
A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
Topics: Adult; Amenorrhea; Amisulpride; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepr | 2001 |
18 other studies available for sulpiride and Weight Gain
| Article | Year |
|---|---|
Dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Diabetes Mellitus, Type 2; Dopamine; Dopami | 2020 |
Effects of sulpiride and ethylene glycol monomethyl ether on endometrial carcinogenicity in Donryu rats.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Carcinogenesis; Carcinogens; Endometrial Hyperplas | 2016 |
Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain.
Topics: Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Female; Humans; Male; Putamen; Reward; Schiz | 2016 |
Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.
Topics: Adolescent; Adult; Amisulpride; Anticipation, Psychological; Antipsychotic Agents; Dopamine D2 Recep | 2016 |
Switching among antipsychotics--focus on side effects.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; D | 2011 |
Behavioral responses are altered in piglets with decreased frontal cortex docosahexaenoic acid.
Topics: Aging; Animals; Animals, Newborn; Behavior, Animal; Brain; Diet; Dietary Fats, Unsaturated; Docosahe | 2003 |
Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Schizophrenia; Sulpiride; Time Factors; We | 2006 |
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Female; Humans; | 2007 |
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, | 2007 |
Hyponatremia and neuroleptic-induced obesity in rats.
Topics: Animals; Drinking; Female; Hyperphagia; Obesity; Potassium; Rats; Rats, Wistar; Sodium; Sulpiride; W | 1994 |
A screening concept based on a hypothesis led to the development of a putative cognitive enhancer that stimulates penile erection.
Topics: Animals; Anorexia; Avoidance Learning; Behavior, Animal; Cognition; Cysteamine; Drug Evaluation, Pre | 1994 |
Mechanism of the neuroleptic-induced obesity in female rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Energ | 1998 |
Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems.
Topics: Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dextroamphetamine; Dopamine; Dopami | 1998 |
Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride.
Topics: Animals; Antipsychotic Agents; Area Under Curve; Blood Glucose; Disease Models, Animal; Eating; Estr | 1998 |
Weight gain: side effect of atypical neuroleptics?
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Body Mass Index; C | 1999 |
Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.
Topics: Animals; Antipsychotic Agents; Diestrus; Eating; Female; Hyperphagia; Naltrexone; Narcotic Antagonis | 2000 |
Mechanisms of weight gain induced by antipsychotic drugs.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Dopamine Antagoni | 2002 |
Ventromedial hypothalamus vs. lateral hypothalamic D2 satiety receptors in the body weight increase induced by systemic sulpiride.
Topics: Amphetamine; Animals; Eating; Female; Hypothalamic Area, Lateral; Injections; Injections, Intraperit | 1991 |